Topics

Human medicines European public assessment report (EPAR): Delstrigo, doravirine / lamivudine / tenofovir disoproxil, HIV Infections, Date of authorisation: 22/11/2018, Revision: 3, Status: Authorised

11:25 EDT 28 Oct 2019 | European Medicines Agency

Human medicines European public assessment report (EPAR): Delstrigo, doravirine / lamivudine / tenofovir disoproxil, HIV Infections, Date of authorisation: 22/11/2018, Revision: 3, Status: Authorised

Original Article: Human medicines European public assessment report (EPAR): Delstrigo, doravirine / lamivudine / tenofovir disoproxil, HIV Infections, Date of authorisation: 22/11/2018, Revision: 3, Status: Authorised

NEXT ARTICLE

More From BioPortfolio on "Human medicines European public assessment report (EPAR): Delstrigo, doravirine / lamivudine / tenofovir disoproxil, HIV Infections, Date of authorisation: 22/11/2018, Revision: 3, Status: Authorised"

Quick Search

Relevant Topic

Reverse Transcriptase
Reverse transcriptase (RT) is an enzyme used to generate complementary DNA (cDNA) from an RNA template, a process termed reverse transcription. It is mainly associated with retroviruses. RT inhibitors are widely used as antiretroviral drugs. RT activitie...